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A B S T R A C T
Background
Methadone maintenance treatment (MMT) is a long term opiod replacement therapy, effective in the management of opiod dependence.
Even if MMT at high dosage is recommended for reducing illicit opioid use and promoting longer retention in treatment, at present
day “the organisation and regulation of the methadone maintenance treatment varies widely”.
Objectives
To evaluate the efficacy of different dosages of MMT in modifying health and social outcomes and in promoting patients’ familiar,
occupational and relational functioning.
Search strategy
We searched:




- Cochrane Controlled Trials Register (CCTR) (1947-2001)
- Register of the Cochrane Drug and Alcohol Group (CDAG) (1947-2001)
The CDAG search strategy was applied together with a specific MESH strategy.
Further studies were searched through:
· letters to the authors
· check of references.
Selection criteria
Randomised Controlled Trials (RCT) and Controlled Prospective Studies (CPS) evaluating methadone maintenance at different dosages
in the management of opioid dependence. Non-randomised trials were included when proper adjustment for confounding factors was
performed at the analysis stage.
Data collection and analysis
Data Extraction was performed separately by two reviewers. Discrepancies were resolved by a third reviewer. Quality assessments of the
methodology of studies were carried out using CDAG checklist.
Main results
22 studies were excluded. 21 studies were included: 11 were RCTs (2279 participants) and 10 were CPSs (3715 participants).
Outcomes: Retention rate - RCTs: High versus low doses at shorter follow-ups: RR=1.36 [1.13,1.63], and at longer ones: RR=1.62
[0.95,2.77].
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Opioid use (self reported), times/w - RCTs: high versus low doses WMD= -2.00 [-4.77,0.77] high vs middle doses WMD= -1.89[-3.43,
-0.35]
Opioid abstinence, (urine based) at >3-4 w - RCTs: high versus low ones: RR=1.59 [1.16,2.18] high vs middle doses RR=1.51[0.63,3.61]
Cocaine abstinence (urine based) at >3-4 w - RCTs: high versus low doses RR=1.81 [1.15,2.85]
Overdose mortality - CPSs: high dose versus low dose at 6 years follow up: RR=0.29 [0.02-5.34] high dose vs middle dose at 6 years
follow up: RR=0.38 [0.02-9.34] middle dose vs low dose at 6 years follow up: RR=0.57 [0.06-5.06]
Authors’ conclusions
Methadone dosages ranging from 60 to 100 mg/day are more effective than lower dosages in retaining patients and in reducing use
of heroin and cocaine during treatment. To find the optimal dose is a clinical ability, but clinician must consider these conclusions in
treatment strategies.
S Y N O P S I S
Synopsis pending
B A C K G R O U N D
Opioid addiction (see CDAG module’s glossary for definition)
is currently defined as a “chronic, relapsing disorder” (Leshner
1997;Dole 1967); this definition, in addition to the epidemiolog-
ical evidence of the drug related risks affecting the addicted pop-
ulation (Brettle 1991; WHO 1991; Ward 1998), has promoted
the development of the “harm reduction” approach in drug ad-
diction treatment (Brettle 1991;Ward 1998). According to this
approach, treatment is aimed to increase time between relapses to
heroin, to reduce intensity, frequency and length of the relapse
(Leshner 1997), cocaine and polysubstance use, overdoses’ risk,
criminal activity, HIV, HBV and HCV infection, and to promote
psychosocial adjustment (Leshner 1997;Ward 1998; Farrell 1994).
Methadone maintenance treatment (MMT) is a long term opi-
oid replacement therapy, implying the daily administration of
methadone, a long acting (24-36 h) opioid drug, and it is the
more common opioid replacement therapy in USA, Europe and
Australia (Ward 1998). Methadone as opioid replacement therapy
was introduced by Dole and Nyswander in the 1960’s (Dole 1965),
as a drug meeting a number of stringent conditions: it “eliminates
the euphoric appeal of heroin and the abstinence symptoms”, it
is “sufficiently free from toxic or dysphoric effects”, it is “orally
effective, long acting, medically safe, and compatible with normal
performance in work and at school” (Dole 1991).
Starting from this model, MMT underwent many changes dur-
ing time from its “popularisation” to the definition of different
goals, such as detoxification, by means of a decrease in dosages
(Ward 1998). Even if MMT at high dosage is recognised to be the
best therapy in “preventing withdrawal and inducing a sufficient
cross-tolerance to heroin, making average street doses non-intox-
icating” (Ward 1994a) and in reducing illicit opioid use and pro-
moting longer retention in treatment (Ward 1998; Farrell 1994),
at present day “the organisation and regulation of the methadone
maintenance treatment varies widely, with explicit guidelines for
programme operation in the United States and Australia and a vir-
tual absence of structure and regulation in Britain” (Farrell 1994),
except for the very recent publication of the clinical management
drug misuse guidelines (Dep. of Health 1999).
The reason for such variability in the use of methadone is mainly
related to the debates that crosses civil society and professional
world. First of all, an agreement has not been reached about the
goal of the treatment, which reflects at the moment different ideas
on the model of the disease. Considering opioid addiction as an
“acute disease” and detoxification as the main aim of the treatment,
some professionals use MMT just as a preparation for a subsequent
detoxification programme. Others consider opioid addiction as a
“chronic disease” and the self-perceived well being of the patients
as the main outcome, use MMT as long term treatment which
allows complete social and personal rehabilitation and prevents
the health damages related to drug use (McLellan 2000). The
differences between this two points of view are not limited to
ethical or deontological considerations, but involve interpretation
of treatment outcomes: for the former a long retention in treatment
is a negative outcome, whereas for the latter it is a positive one
(McLellan 2002).
The debate concerns not only clinicians but also policy makers,
politicians and the general population, for which the maintenance
concept is related to the “prescription of a drug which causes de-
pendence”, and this idea leads to a sort of defection of the treat-
ment, being not naturally aimed to the total recovery of the subject.
This disagreement, mostly not scientific, must be taken to a more
technical debate about dosage. The findings of most studies agree
in indicating high dosage (>60 mg) as the more effective for the
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outcomes above stated, whereas only a few authors state that low
doses are effective as higher to prevent withdrawal (Wolff 1994).
Moreover, a systematic review on methadone maintenance therapy
versus no opioid replacement therapy for opioid dependence have
been published (Mattick 2003), but the issue of differential efficacy
of different dosages has not been addressed.
All these reasons suggest a need for metanalytic and unbiased re-
views addressing the above mentioned questions, and possibly
clarifying which are the more protective dosages of methadone
maintenance treatment (MMT) for the health of drug addicted
people.
O B J E C T I V E S
To evaluate the efficacy and safety of different dosages of MMt
for opiod dependence, in modifying health and social outcomes
and in promoting patient’s familial, occupational and relational
functioning
C R I T E R I A F O R C O N S I D E R I N G
S T U D I E S F O R T H I S R E V I E W
Types of studies
Literature was reviewed for all of the RCTs, CCTs and the
prospective studies evaluating methadone maintenance at differ-
ent dosages in the management of opioid dependence. Controlled
Prospective Studies were included when proper adjustment for
confounding factors was performed at the analysis stage.
Types of participants
Opioid addicted patients were the target population for this review.
No distinction was made between those using heroin and those
who have been in methadone treatment prior to entering the study.
No restriction were imposed in terms of inclusion or exclusion
criteria, but studies focused on pregnancy status were excluded
from the review.
Types of intervention
Comparison between two or more different dosages of MMT (also
when compared with other kind of treatment or with placebo
in a third arm), independently from the duration (duration was
introduced as a stratification item).
Types of outcome measures
Outcome variables examined in this review were dichotomous (D)
or continuous (C).
- Retention in treatment
measured by:
• time a participant remains in treatment - C
• retention rate at a given time - D
- Drug use during treatment
measured by:
• use of opioid or cocaine, based on urinalysis - D, or based on
self-report - C
- Long term abstinence after treatment
measured by:
• abstinence from opioid, at a given time after the study begin-
ning, based on urinalysis - D, or based on self-report - C
- Opiod amount used
measured by:
• the amount used per day - C
• dollars spent per day - C
- Opiod and cocaine withdrawal symptoms (based on analogical
scales, self-reported - C)
- HIV, HBV and HCV seroconversion (a negative test at the be-
ginning of the study, followed by a positive one - D)
- Risk infection behaviour
measured by:
• sharing needles and other tools, self reported - D
• sexual behaviours, self reported - D
- Work activity
measured by:
• changes in work activity (based on self reports or official docu-
ments - D)
- Criminal activity
measured by: - incarceration, reincarceration for parolees or pro-
bationers during/after the study period (based on self reports or
official documents - D)
- Psychological adjustment
measured by: - level of psychological equilibrium (based on ques-
tionnaire reports, specific scales - C)
- Side effects
measured by:
• type and number of undesired pharmacological effects caused
by the medication under study (based on self reports or clinical
records - D, C)
- starting consumption of cocaine (based on self reports or clinical
records - D, C)
- Mortality during/after the treatment (for all causes, for overdose
and for acute diseases - D)
Different factors were considered as confounders and taken into
account in the analysis where possible:
- age, sex, ethnicity
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- education level, employment status, income
- marital status, family status
- needle sharing
- frequency of injection, route of injection
- current use of alcohol, benzodiazepine, cocaine
- HIV status
- duration of injection, age of first consumption
- previous MMT, previous MMT failure
- centre policy
S E A R C H S T R A T E G Y F O R
I D E N T I F I C A T I O N O F S T U D I E S
See: Drugs and Alcohol Group search strategy
The following sources were used:




• Cochrane controlled trials Register (CCTR) (1947-2001)
• Register of the drug and alcohol group (CDAG) (1947-2001)
We looked for studies:
• from 1947, year of publication of the first study on the use of
methadone to treat opiate withdrawal syndrome (Payte 1991)
• to December 2001
• languages: all
We applied the following strategies:
• CDAG strategy
• MESH strategy including the following terms: methadone.mp
or [exp Substance-related disorders/ AND (Program
evaluation/ OR Substance abuse treatment centres OR
Treatment Failure/ OR Treatment outcome/ OR Drug
therapy/ OR Drug Therapy, combination/ OR preventive
psychiatry/ OR exp Psychotherapy/ OR Community health
services/ OR Therapeutic community/ OR exp Community
health Centres/ OR harm reduction.tw.)]. Editorials, reviews,
commentaries, letters to the editor were included in the set.
Review articles, as well as all the included and excluded studies
cited in the review were scanned to identify relevant studies.
Relevant editorials, commentaries, letters were reviewed to
identify useful bibliography.
A search of other published or unpublished studies known or
conducted by the authors of the primary studies was made to
find other relevant studies.
Personal contacts with other research and review teams working
in the field, as well as with authors of the included studies was
made to identify other potentially relevant studies.
M E T H O D S O F T H E R E V I E W
We adopted a four stages process to select studies to be included
in the review:
1. Records retrieved from each database were stored on ProCite;
titles were pre-screened for relevance excluding the articles not
related to the subject under study, by using specific search terms
or search expressions.
2. The studies not excluded above were assessed by reading the
abstract. The abstract were sifted separately by two reviewers to
evaluate relevance and each study was excluded according to the
following criteria:
· if it was clearly not focused on opioid dependence
· if it was clearly not focused on methadone at different dosages
· if it was clearly not a RCT, a CCT or a CPS, or anyway a controlled
study
· if it clearly did not present results
A study was excluded when meeting at least one of the above listed
criteria.
In case of disagreement the study was included in the next step.
3. Each potentially relevant study not excluded in the previous
steps was obtained and was independently assessed by two
reviewers, in order to include it definitely.
4. The assessment of the internal quality of the included studies
was done by two reviewers according to the CDAG’s check list
(Ferri 2003). The CDAG’s system was used to weight the criteria
used to evaluate the studies. For experimental studies (RCTs and
CCTs) randomisation, allocation concealment, blinding, losses to
follow-up and criteria defined as “others” (baseline comparability
of the groups and absence of performance bias) were carefully
examined, and a quality score was determined based on fulfillment
of these criteria. For prospective studies (CPSs) population base
and confounding adjustment, inclusion of all patients in the
analysis and criteria defined as “others” (adequate description of
the base and of the treatments) were the main characteristics
examined to formulate the quality score. A threshold for exclusion
was identified.
Using this system, studies were finally classified in 3 classes
according to quality:
A low risk of bias (all criteria met or one criteria partially met)
B moderate risk of bias (a maximum of two criteria partially met)
C high risk of bias (three or more criteria partially met or at least
one criteria not met)
Any disagreement has been resolved by a third reviewer.
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According to quality, data extraction from included studies
and quantitative analysis was performed by two reviewers
independently. A standardized checklist was used for data
extraction. Disagreement was dealt with by the third reviewer,
acting as a mediator.
The authors of studies which needed integration of results were
contacted, and the reference put into the “Awaiting assessment”
section. Two of them (D’Ippoliti 1998; Torrens 1996) provided
the requested integrations, allowing the inclusion of the data in
the metanalysis.
For Controlled Prospective Studies, which needed a proper
adjustment for confounding factors to be included in the review,
the absolute number of subjects in the numerator of occurrence
measures given by authors in the papers were unadjusted, and only
presented RRs were adjusted for confounding. To fill RevMan
tables, which need absolute number of subjects of numerator and
denominator measures to provide figures, “adjusted numbers” of
numerators were then re-calculated as follows: absolute number of
subjects in the numerator of the control group were kept fixed and
“adjusted numbers” of subjects with the occurrence under study in
the treatment group were re-calculated as product of the adjusted
RRs by the absolute numbers of the control group. The fictitious
adjusted numbers of events in the intervention group so obtained
were put in the tables together with the initial number of subjects
in the control group to compare the effects among the studies.
Some CPSs studies did not present data useful for the inclusion
in the metanalysis (Caplehorn 1991; Caplehorn 1994; Caplehorn
1996; Gaughwin 1998; Gossop 2001; Maddux 1997): they mainly
used Cox regression statistical analysis, providing a RR of leaving
treatment according to a continue increase in methadone dose.
For these studies, data were extracted converting the provided
measures in RRs at specific dosages (30 mg, 60 mg, 90 mg/day);
they were summarized in the Addictional Table 01.
We used the RevMan software for the analysis. RCTs and CPSs
were analysed separately.
For each study finally included the main results were reported in a
table, in which methadone use was presented in classes of dosage,
in order to pool together arms subjects with similar exposition to
methadone. An evaluation by length of follow-up was made for
retention rate. To standardized the outcomes measured with time
scales, days were converted into weeks. The different withdrawal
symptoms point scales were converted into a standardized 75-
point scale, in order to make possible comparison among the
studies.
For RCTs, included results were grouped into the following
methadone dosages: 1-39 mg/day, 40-59 mg/day; 60-109 mg/
day, >110 mg/day.
For CPSs, because of a slight overlapping among the categories
presented in the studies, results were presented for the outcome
“leaving treatment” grouped into three broad groups: low dose,
middle dose, high dose. In fact, Del Rio 1997 provided RRs
comparing 15-40 mg/day, 45-60 mg/day and 65-110 mg/
day; D’Ippoliti 1998 compared <30 mg/day, 30-59 mg/
day and >=60 mg/day; Torrens 1996 compared <=80 mg/
day and >80 mg/day. For the outcome “mortality” the
categories of the only study included (Van Ameijden 1999)
were maintained: 5-55 mg/day, 55-70 mg/day, >75 mg/
day.
A standardized effect size was calculated for each study, based on
the outcomes reported. Where possible, relative risk and 95%
confidence intervals were calculated through a fixed effects model,
and for continuous outcomes a weighted mean difference between
groups was presented. To assess for statistical heterogeneity, a test
of homogeneity was performed.
In order to assess the effect of the low quality studies on the
synthetic results, all included studies were submitted to a sensitivity
analysis, either including or excluding the class C ones.
Results were integrated from the meta-analytic review into
a discussion taking into account other relevant publications.
Convergence between the meta-analysis results and the narrative
review was taken to indicate strong evidence of the effect.
D E S C R I P T I O N O F S T U D I E S
The information provided in the tables present the characteristics
of the excluded and the included studies.
Excluded studies
Twenty-two studies were excluded from the review.
Three were RCTs; the study by Havassy (Havassy 1984) was ex-
cluded because the randomization process failed, and there was
inadequate control of confounding variables to use it as a CCT.
The study by Panell (Panell 1977) and the study by Strain (Strain
1993b) presented secondary analysis of subsamples of the original
trials (Ling 1996 and Strain 1993a), included in the review. In the
study by Saxon (Saxon 1996), the comparison was made between
contingency and non-contingency approaches and not between
doses.
All the other excluded studies were CPSs; they were mainly ex-
cluded because of inadequate control of confounding variables,
except for the studies by Caplehorn (Caplehorn 1993a; Caple-
horn 1993b) which presented a secondary analysis of the original
study (Caplehorn 1991), included in the review. The study by
Hartel (Hartel 1998) used a retrospective ascertainment of the
exposure; Langendam (Langendam 2000a) did not evaluate the
effect of methadone dosage in the multivariate analysis, whilst
the study by Stine (Stine 1992) evaluated the effects of different
contingency approaches and not of methadone dosages.
Included studies
In total, 21 STUDIES (26 reports) were included in the review.
• Study design
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Eleven studies were RCTs, ten were CPSs; six of them did not
present data useful for the inclusion in the metanalysis, because of
the statistical model used for the analysis; however, they provided
results which can be presented in a narrative way.
• Length of follow-up
RCTs: range 7-52 weeks
CPSs: range 1-10 years
• Setting








Among RCTs, five studies compared buprenorphine and
methadone treatment, and at least two arms had different
methadone dosages with 643 subjects involved (Johnson 1992;
Kosten-Oliveto 1993; Ling 1996; Schottenfeld 1997). One study
compared levomethadyl acetate and two different methadone
dosages with 430 subjects involved (Ling 1976 ), and one study
compared levomethadyl acetate, buprenorphine and two different
methadone dosages with 220 subjects involved (Johnson 2000).
Three studies with 559 subjects involved (Goldstein 1973Strain
1993a; Strain 1999) were focused on the comparison of different
dosages of methadone. In the study by Rhoades, 142 subjects in-
volved (Rhoades 1998), subjects were randomly assigned to two
methadone dosages and to two or five visit per week, no results
were however useful for the inclusion in the metanalysis. The re-
maining study (Preston 2000) evaluated interventions based on
contingent vouchers, and two methadone dosages, combined in
different ways: for our analysis we used the groups which received
non-contingent vouchers, which involve 285 subjects.
RCTs (see “comparison and data” for the outcomes): eleven studies
and 2279 subjects.
Comparison 1: 60-109 mg/day vs 1-39 mg/day (at 17-26 weeks)
(Johnson 1992; Johnson 2000; Kosten-Oliveto 1993; Ling 1996;
Schottenfeld 1997)
Comparison 2: 60-109 mg/day vs 1-39 mg/day (at 52 weeks) (Ling
1996)
Comparison 3: 60-109 mg/day vs 40-59 mg/day (at 7-13 weeks)
(Ling 1976; Preston 2000)
Comparison 4: 60-109 mg/day vs 40-59 mg/day (at 27-40 weeks)
(Goldstein 1973; Ling 1976; Strain 1999)
Comparison 5: 40-59 mg/day vs 1-39 mg/day (at 20 weeks) (Strain
1993a)
Comparison 6: >110 mg/day vs 40-59 mg/day (at 27 weeks)
(Goldstein 1973)
Comparison 7: >110 mg/day vs 60-109 mg/day (at 27 weeks)
(Goldstein 1973)
CPSs, outcome “mortality”, one study and 498 subjects (Van
Ameijden 1999):
Comparison 1: >75 mg/day vs 5-55 mg/day
Comparison 2: >75 mg/day vs 55-70 mg/day
Comparison 3: 55-70 mg/day vs 5-55 mg/day
CPSs, outcome “leaving treatment”, three studies and 1202 sub-
jects (D’Ippoliti 1998; Del Rio 1997; Torrens 1996):
Comparison 1: high dose vs middle dose
Comparison 2: middle dose vs low dose
Comparison 3: high dose vs low dose
Details on the comparison groups are available in the Character-
istics of Included Studies tables.
• Outcomes
All included studies were assessed to determine whether they pro-
vided data for the outcomes measure of interest, including reten-
tion in treatment, heroin and cocaine use by urinalysis, self-re-
ported heroin and cocaine use, long-term abstinence, withdrawal
symptoms, amount of drug used per day, criminal activity, HIV,
HBV and HCV sero-conversion, overdose and all-causes mor-
tality. After reviewing the studies, it was realized that it was not
possible to include urine results for heroin and cocaine use when
these were not reported at an individual level; most part of the
studies provided in fact proportions of positive tests calculated as
the number of positive tests divided by the total of number of tests
carried out, and using tests instead of subjects as a unit of analy-
sis: this procedure violates the hypothesis of independence among
observations (Ferri 2003). Only two studies, showing results at an
individual level (percent of patients abstinent), could be included
in the metanalysis (Johnson 2000; Schottenfeld 1997). Authors
will be contacted in order to provide urine data at a individual
level.
Among CPSs, three studies (D’Ippoliti 1998; Del Rio 1997; Tor-
rens 1996) were focused on risk of leaving treatment as outcome,
whilst one study evaluated the effect of dosages on mortality rate
(Van Ameijden 1999).
M E T H O D O L O G I C A L Q U A L I T Y
RCTs
Of the eleven RCTs included in this review, nine were conducted
under double blind conditions (Johnson 1992; Johnson 2000;
Kosten-Oliveto 1993; Ling 1976; Ling 1996; Preston 2000; Schot-
tenfeld 1997; Strain 1993a; Strain 1999), and two under single
blind conditions (Goldstein 1973; Rhoades 1998). In order to
maintain the double-blind approach, it was generally used a dou-
ble-dummy procedure: for example, comparing methadone with
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buprenorphine, patients were given both an oral solution and a
sublingual preparation.
Only one of the eleven studies (Strain 1999) described in detail
a method of allocation concealment, which was adequate: assign-
ments were sealed in numbered envelopes, and dose codes were
entered into a database accessible only to pharmacy staff and se-
lected research assistants with no patients contact. All the other
studies did not describe allocation concealment procedures in suf-
ficient detail to be clear that the allocation concealment method
was adequate. There were no trials where the concealment method
could be defined as clearly inadequate.
Five of the eleven studies described the randomisation process
(Strain 1999; Schottenfeld 1997; Preston 2000; Ling 1996; John-
son 2000); all the others mentioned it without any description.
The characteristics of the patients and the inclusion and exclusion
criteria were generally well defined in all the studies. Similarity of
the treatment groups at the start of the trial was generally good,
except for two studies (Rhoades 1998; Johnson 1992).
The completion of the follow-ups was generally quite high, or it
was used an intention to treat analysis. The number of partici-
pants varied between 116 subjects (Schottenfeld 1997) up to 430
subjects (Ling 1996).
According to these criteria, five RCTs (Strain 1999; Schottenfeld
1997; Preston 2000; Ling 1996; Johnson 2000) were evaluated as
high quality studies (class A), five (Goldstein 1973; Ling 1976;
Kosten-Oliveto 1993; Strain 1993a; Johnson 1992) as moderate
quality studies (class B), and one (Rhoades 1998) as low quality
study (class C). To perform sensitivity analysis it was considered
in this case not necessary, because the low quality class study did
not provide useful data for the tables, and all the other studies had
high or moderate quality.
CPSs
Of ten CPSs included in this review, four provided data on re-
tention by classes of methadone dosage (D’Ippoliti 1998; Del Rio
1997; Torrens 1996; Van Ameijden 1999), whilst, as mentioned
in the Methods section, six provided a measure of risk according to
a continuous increase of methadone dose. All the studies provided
an adequate description of the population base, clear inclusion
and exclusion criteria. The number of participants varied between
111 (Del Rio 1997) up to 721 (D’Ippoliti 1998).
For outcomes such as retention or leaving treatment, it was not
proper to evaluate losses to follow-up as a criteria to discriminate
high and low quality studies. The adjustment for confounding
variables was the main criteria used to judge the quality of the
CPS studies. Because of poor adjustment, two of them (Del Rio
1997; Gossop 2001) were classified as low quality studies (class
C), whilst all the others were judged as moderate quality studies
(class B). It was in fact impossible to exclude residual confounding.
Sensitivity analysis was performed in order to evaluate the effect
of low quality studies on the main outcome (treatment retention).
Keeping the low quality study in the review did not significantly
change the results, so it were kept on.
R E S U L T S
• Treatment retention
RCTs
Retention in treatment has been studied through relative mea-
sures of retention and time in treatment, according to the type of
indicator found in the included papers.
Retention rates
As presented in the Methods section, 22 arms of 10 Randomised
controlled trials has been classified, according to the used range
of dose, in 4 groups of exposure: 1-39 mg/day, 40-59 mg/day,
60-109 mg-day and 110+ mg/day. These four arms were stratified
in 2 different follow-up periods. absolute values of retention rates
ranged from 20% (low dose, medium follow-up; Johnson 1992)
to 96% (medium dose, short follow-up; Ling 1976).
High doses, ranging from 60 to 109 mg/day, showed better reten-
tion rates than low doses (1-39 mg/day) both in shorter follow-ups
(RR=1.36 [1.13,1.63]) (five studies, 247 patients in the treatment
arm and 249 patients in the control one, Johnson 1992; Johnson
2000; Kosten-Oliveto 1993; Ling 1996; Schottenfeld 1997), and
in longer ones (RR=1.62[0.95,2.77]) (one study, 75 patients in
the treatment arm, Ling 1996). Retention rates ranges from 20%
(low doses; Johnson 1992) to 70.9% (high doses; Johnson 2000).
High doses compared with medium doses (40-59 mg/day) seemed
to show differences in effectiveness only for follow-ups longer than
27 weeks (RR=1.23 [1.05,1.45]) (three studies, 277 patients in
the treatment arm and 283 controls, Goldstein 1973; Ling 1976;
Strain 1999), whereas for shorter follow-up no differences has been
evidenced (two studies, 173 patients in the treatment arm and 174
controls, Ling 1976; Preston 2000).
Only one study compared medium doses with low doses, and the
RR of 1.26 [0.91,1.75] appeared to be affected by random error
(Strain 1993a, 84 patients in the treatment arm and 82 controls).
Very high doses appeared to be more effective compared with
medium doses (RR=1.67 [1.05,2.66]) (Goldstein 1973, 40 pa-
tients in the treatment arm and 40 controls) but not with high
doses (RR=0.96 [0.69,1.34]) (Goldstein 1973).
The dose relationship in retention rates in the only study with
more than 2 arms (Goldstein 1973) show the following results at
27 weeks follow-up: very high doses 62.5%, high doses 62.0%
medium doses 37.0%, with a significant effect of very high and
high doses vs middle ones, but without significance from very high
doses and high ones.
Retention time
Four RCTs (Johnson 2000; Kosten-Oliveto 1993; Preston 2000;
Rhoades 1998) presented results on retention as time function.
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Length of retention were expressed as means and standard de-
viations in a specific arm, as they were reported in the article,
and ranged from 12.6 weeks (high dose arm, Preston 2000) to
19.6 weeks (high dose arm, Schottenfeld 1997). Whereas high
compared to medium did not show differences (WMD=-0.30
weeks [-0.77,0.17] (Preston 2000, 31 patients in the treatment
arm and 28 controls), high doses seemed to be more effective
when compared with low doses (WMD=3.54 weeks [2.19,4.89])
(three study, 118 patients in the treatment arm and 119 controls,
Johnson 2000; Kosten-Oliveto 1993; Rhoades 1998).
CPSs
Height of ten Controlled Prospective Studies included data on
retention in the papers. Three of them showed data useful to be
included in the metanalysis (D’Ippoliti 1998; Del Rio 1997; Tor-
rens 1996), whereas results from the others are presented in the
Additional Table 01. Seven studies analysed retention as the risk
of leaving treatment, while one as the risk of staying in treatment.
Results from observational studies seems to confirm those from
randomised trials: high doses are always protective for leaving treat-
ment, but in the study of Del Rio 1997. For studies included in
metanalysis, relative risks ranged from 0.68 [0.51-0.89] for high
vs middle dose (two studies, 191 patients in the treatment arm and
423 controls, D’Ippoliti 1998; Del Rio 1997) to 0.35 [0.27,0.45]
for high dose compared to low dose (three studies, 317 patients in
the treatment arm, 396 controls, D’Ippoliti 1998; Del Rio 1997;
Torrens 1996). For studies presented in the additional Table 01,
RR of leaving treatment at different times from starting varies
from 0.56 to 0.40 for medium doses treatments compared to low
doses, and from 0 to 0.28 for high doses compared to low doses
(all comparisons are statistically significant). The study of Maddux
1997 considered the risk of retention instead of the probability of
leaving; higher doses treatments show a statistically significant RR
of 2.32 to be retained at 1 year, when compared to low doses main-
tenance. Medium dose vs low dose show a statistically significant
RR of 1.66 at 1 year follow-up.
• Heroin use
RCTs
The relationship between methadone dose and use of heroin is
reported by 3 RCTs and 1 included CPS, in 5 different ways.
Two studies (Preston 2000; Johnson 2000) reported the mean
number of times/week of use of heroin: high dose compared to low
dose reduce the use of heroin as far as 2 times/week (Johnson 2000,
55 patients in the treatment as well in the control arm); high dose vs
medium dose reduce also the amount of heroin consumed (Preston
2000, 31 patients in the treatment arm, 28 controls) and increase
the number of periods of opioid abstinence longer than 3 weeks
(Preston 2000; Johnson 2000; Kosten-Oliveto 1993; Schottenfeld
1997); the result is statistically significant for high compared to
low doses (RR=1.59 [1.16,2.18]) (three studies, 118 patients in
the treatment arm, 119 controls, Johnson 2000; Kosten-Oliveto
1993; Schottenfeld 1997). One RCT (Ling 1996, 75 patients in
the treatment as well in the control arm) uses a specific abstinence
score, based on number of weeks of abstinence, showing its increase
using high vs low doses.
CPSs
Only one of the included CPS reported results on use of heroin
(Gossop 2001), showing a RR of 0.98 [0.97,0.98] for the reduc-
tion in use of heroin for each mg increase of average methadone
dose.
• Opioid withdrawal symptoms
RCTs
Two studies addressed the question on the role of methadone dose
in reducing withdrawal symptoms (Preston 2000; Kosten-Oliveto
1993). The increase of dose seems to reduce the symptoms of
withdrawal, but the results are not statistically significant, either
in the comparison high vs medium dose (Preston 2000, 31 patients
in the treatment group, 28 controls), or in the high vs low dose




Three studies addressed the question on relationship between the
dosages of the methadone treatment and the use of cocaine. Re-
sults from one of them are based on self reported frequency of use
(Kosten-Oliveto 1993), and it suggests a non significant excess
of use of cocaine among subjects treated with higher doses com-
pared with subjects treated with lower doses (29 patients in the
treatment arm, 30 controls). Two studies used the frequency of ab-
stinence period longer than 3 weeks, based on urine analysis, and
the pooled results showed that high dose increase the probability
to stay abstinent from cocaine, compared with low dose (RR=1.81
[1.15,2.85]) (Johnson 2000; Schottenfeld 1997, 83 patients in the
treatment arm, 85 controls). One study reported a high propor-
tion of positive tests for cocaine in patients treated with higher
methadone doses (Rhoades 1998); it was based on urinalysis and
not on individuals and could not be used in the metanalysis, as
explained in the Cochrane Drug and Alcohol module (Ferri 2003).
• Cocaine withdrawal symptoms
RCTs
No effect of methadone doses has been showed by the only study
addressing this question (Kosten-Oliveto 1993, 29 patients in the
treatment arm and 30 controls).
• Side effects
RCTs
No significant differences are evident for side effects, included
in COSTART list (FDA 1985), for high doses compared to low
(Johnson 2000, 55 patients in the treatment as well in the control
arm).
• Criminal activity
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RCTs
No significant differences are evident for mean number of crim-
inal activities in the comparison between high dose and medium
dose in the only study focusing on this outcome (Preston 2000,31
patients in the treatment arm, 28 controls).
• Money spent
RCTs
Subjects under treatment with higher doses appears to spent less
money for illicit drugs than those under treatment with medium




Only one CPS studied the outcome mortality, and in spite of the
high number of subjects involved in the study, the results are not
statistically significant (Van Ameijden 1999, 498 patients); never-
theless, all contrasts between dosages showed protective effect for
higher dosages, with a clear suggestion of a dose response relation-
ship.
D I S C U S S I O N
This review is based on 11 RCTs and on 10 CPSs, included
after a careful assessment of scientific validity. Its main re-
sult is that methadone maintenance is a dose-dependent treat-
ment. The higher doses of methadone are associated with
better retention in treatment, less heroin use during treat-
ment and lower withdrawal symptoms, until around 100 mg/
day, after that the reliability of evidence is lower. The effect of
dose on risk of death and on criminal activities can not be reli-
ably assessed because the only study addressing these objectives
have not sufficient power to obtain significant results. The prob-
ability to stay abstinent from cocaine is higher with high doses of
methadone, compared with low doses. No side effects are evident
from studies. No more socially relevant outcomes nor infectious
diseases risks has been searched by the studies included in the
review.
The effectiveness of higher doses of methadone in promoting re-
tention, reducing heroin and promote abstinence from cocaine
is consistent within included studies and with pharmacokinetic
observations (Ward 1998; Hiltunen 1999). The excess of cocaine
use in treatment with higher doses reported by Oliveto (Kosten-
Oliveto 1993) can be an effect of chance. Cocaine can be used by
methadone maintained patients for different reasons, including
antagonism of opioid sedative effects, searching for euphoria inde-
pendent from methadone “blockade” and to suppress opioid with-
drawal. The risk of increasing use of cocaine during methadone
maintenance treatment reported by some authors (Tennant 1995;
Stine 1991)can be an effect of the underdosing of methadone and
higher doses of this medicament should stop use, as showed by this
review. Nevertheless the risk of cocaine use in methadone main-
tenance can be taken carefully into consideration in the choice
of patient treatment given that non effective treatments are avail-
able nowadays to contrast cocaine use (Lima 2003a; Lima 2003b;
Soares 2003).
The use of higher doses of methadone for the aim of retain patients
and stop their use of heroin seems to be effective; however the pro-
fessional community showed some resistance in accepting such a
treatment modality (D’Aunno 1999; Farrell 1994; Baillie 1992;
Ward 1994b). This is to a certain extent driven by ideological as-
sumption about the nature of opioid addiction (Rawson 1991),
but partly is due to the management of the treatment by the staff:
in general the patient and the staff determine together methadone
dosages (Langendam 2000b), and sometimes the patient asks for
lower doses, sufficient to contrast withdrawal symptoms but not
to neutralise heroin euphoric effects. The availability of system-
atic reviews on evidence of effectiveness may contribute to the
implementation of higher doses treatments.
The low number of studies aimed at studying the influence of
methadone dosage in mortality is not surprising; although death
is the outcome that can better act as a global indicator of success
of treatment, nevertheless death is fortunately a seldom event,
even in a high risk population like drug users, and to reach the
needed statistical power to study mortality requires big RCTs or
long follow-up periods. Observational studies appears to be less
complex to carry out for the assessment of the relationship between
treatment and mortality, as the study included in our review (Van
Ameijden 1999).
This review takes into consideration observational studies together
of randomised trials. All studies have been critically appraised us-
ing the Cochrane Drug and Alcohol Group methodology (Ferri
2003), and randomised and observational studies have been anal-
ysed separately, to avoid bias. In conclusion of the review, we can
affirm that observational studies showed results which are consis-
tent with those from randomised studies, and they add a relevant
outcome not assumed by RCTs, the risk of death.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The results of the review support the conclusion that methadone
dosages ranging from 60 to 100 mg/day are more effective than
lower dosages in retaining patients and in reducing use of heroin
and cocaine during treatment. To find the optimal dose is a clinical
ability, but clinician must consider these conclusions in treatment
strategies. The most important side effect is the risk of increase
the use of cocaine, which therefore needs to be carefully surveyed
by clinicians.
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Implications for research
The main implications for research concern open questions and
methodological errors of studies.
There are many questions that remain without answer:
• there are some major outcomes for which data are absent or
unsatisfactory: the effect of methadone dose in mortality re-
duction is the most important one. In general social outcomes
are seldom addressed by researchers, and we do not have reli-
able answer to the question if there is the same dose-response
relationship, as found for retention and use of heroin, for crim-
inality or social adjustment;
• cocaine use during methadone maintenance is a major problem,
and no effective medication is available; further research on
effective treatments is needed, either pharmacological or not;
• both higher dosages and psycho-social interventions associated
to methadone are able to improve outcomes, but the interaction
between these two treatments modalities is unknown;
• one of the open questions is if different characteristics of pa-
tients can determine different needs as regards methadone ef-
fective doses. Some authors suggest that patients with less severe
dependence can be successfully treated with doses lower than
50mg per day (Ward 1994b), but no studies addressed at the
moment such a question.
On the methodological point of view, main problems which
should be avoided in further research on methadone dosages are:
• the heterogeneity of outcome indicators: to aid comparison be-
tween studies, which is the main objective of the science, and to
simplify synthesis of results, each author should make effort to
adopt both outcome indicators and categorisation of outcomes
already adopted by other studies. The editors of scientific jour-
nal, scientific societies and all the scientific community, should
promote the use of standards in reporting results (CONSORT
2001);
• the control of confounding remain the major methodological
reason for the exclusion of observational studies. Given that
non-randomised trials are essential to study rare outcomes, such
as mortality, and to address questions on effectiveness of treat-
ments, researchers should play a major effort to improve the
study design particularly in confounding adjustment.
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Participants 238 individuals with a history of opiate addiction and current illicit opiate use confirmed by urinalysis,
entering methadone maintenance treatment at two clinics in Sydney, Australia, between February 1986 and
August 1987.
Interventions Methadone maintenance at different dosages, measured by maximum daily dose.
Outcomes Time in treatment.
Socio-demographic and methadone dose data were extracted from clinical records.
Notes No data suitable for inclusion in the tables.





Participants 307 individuals with a history of addiction to illicit opioids admitted into methadone maintenance in the
Parramatta programme before 1 July 1979. Study period ended 1 January 1991.
New South Wales, Australia.
Interventions Methadone maintenance at different dosages, measured by maximum daily dose.
Outcomes Time in treatment.
Socio-demographic data, methadone treatment history, methadone dose data were extracted from clinical
records.
Subjects who had died prior to the end of the study period were identified checking the NSW Registry of
Births Deaths and Marriages.
Notes No data suitable for inclusion in the tables.
Cox regression model.





Participants 280 heroin addicts entering 10 methadone programs operated by independent, private physicians between
1989 and 1992.
Sydney, Australia.
Interventions Methadone maintenance at different dosages, measured by maximum daily dose.
Outcomes Time in treatment.
Socio-demographic data, methadone treatment history, methadone dose data were extracted from clinical
records.
Notes No data suitable for inclusion in the tables.
Cox regression model.
RR of leaving treatment (maximum dose 100 mg/day vs maximum dose 50 mg/day).
Allocation concealment D
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Participants 721 drug users entering methadone maintenance in the first 6 months of 1995. Lazio Region, Italy.
Interventions Methadone maintenance at different dosages:
- <30mg (n=113)
- 30-59 mg (n=384)
- >= 60 mg (n=158)
Outcomes Treatment retention at 1 year follow-up. RRs adjusted by main confounders.
Notes Baseline group for RR: <30 mg/day.
Allocation concealment D
Study Del Rio 1997
Methods CPS
quality class: C
Participants 111 adults patients attending a methadone treatment programme in Geneva, Switzerland between February
1991 and January 1995. Inclusion criteria: age of over 18 years, a history of addiction to opiates for more
than 2 years and 2 previous drug rehabilitation attempts.
Interventions Methadone maintenance at different dosages:
- 15-40 mg/day (n=39)
- 45-60 mg/day (n=39)
- 65-110 mg/day (n=33)
Outcomes Treatment retention at 18 months.
Programme failures included dropouts, imprisonment, administrative discharge, death for a condition con-
tracted while in program. Programme successes included patients still in the program at the end of follow-up,
transfers to other doctors after stabilization, termination of program agreed with the physician, imprisonment
for an offence committed before entering the program.
All patients were followed until they quit the programme or until 31 July 1995, whichever came first.
Notes Prevalent subjects.
Only few confounding factors are taken into account.





Participants 229 participants randomly sampled from the 1239 drug addicted people enrolled for the first time in the
methadone program between January 1981 and June 1991, plus for 40 HIV positive participants who
enrolled in the program during the same period.
Adelaide, Australia.
Interventions Methadone maintenance at different dosages, measured by maximum daily dose.
Outcomes Treatment retention.
Time spent on initial program.
Notes No data suitable for inclusion in the tables.
Cox regression model. RR of treatment retention per increase in maximum dose of methadone.
Allocation concealment D
15Methadone maintenance at different dosages for opiod dependence (Review)
Copyright ©2005 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
Characteristics of included studies (Continued )
Study Goldstein 1973
Methods RCT - Single blind, randomized clinical trial.
quality class: B
Participants 120 patients enrolled from the East Valley Clinic and Santa Clara County Methadone Program, Stanford,
California. Study period not specified.
Interventions For the first 9 weeks (phase I) all patients were treated identically: the induction dose (30 mg/day) was
repeated for 2 days, then 10 mg/day increase were administered daily reaching the stabilization dose (80 mg/
day). From week 10th to 16th (phase II) increases or decreases of dose were administered to the intervention
groups for which the stabilization doses were 160 and 40 mg/day.
From week 17th to 27th (phase III) subjects were maintained at the stabilization dose:
- 160 mg/day (n=40)
- 80 mg/day (n=40)
- 40 mg/day (n=40)
Outcomes Treatment retention at 27 weeks (10 weeks treatment).
Self reported withdrawal symptoms.
Use of drugs measured by urine samples collected on a random basis, one day in five on the average, and






Participants Random stratified sample of 351 patients selected among subjects with complete methadone dosage data in
the NTORS National UK Cohort between March and July 1995.
Interventions Methadone Maintenance (n=240) and Methadone Reduction (n=111).
Outcomes Treatment retention.
Self reported regular heroin use (more than once a week) at 2 years from the beginning of the treatment.
Notes No data suitable for inclusion in the tables.
ITT analysis.
OR of heroin use per each mg of increase in methadone dose.
Allocation concealment D
Study Johnson 1992
Methods RCT - Randomized, double blind, double-dummy clinical trial.
quality class: B
Participants 162 unpaid volunteers enrolled between September 1988 and November 1989. 53 subjects treated with
buprenorphine, 109 subjects treated with methadone.
Inclusion criteria: 21-50 years old, self-reported lenght of present addiction of at least 4 months, two or
more episodes of heroin use per day, self reported daily value of heroin use of $50 or greater, self reported
withdrawal symptoms, three consecutively collected daily urines, at least two of which positive for opioids, no
current methadone treatment. No acute or chronic medical or psichiatric illnesses, no pregnancy. Baltimore,
USA.
Interventions Patients were assigned to one of three treatment groups:
- 20 mg methadone/day (n=55)
- 60 mg methadone/day (n=54)
- 8 mg buprenorphine/day (n=53)
180-day study: 17 weeks of induction/maintenance phase, then detoxification.
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High dose was accomplished by administering 20 mg as the first dose, then 10 mg increase were administered
daily. For low dose induction: 20 mg as first dose, followed by 30 mg for 4 days, 25 mg for 4 days and then
20 mg daily.
Patients received treatment with both oral and sublingual doses daily.
Counseling for relapse prevention was offered but not mandatory.
Outcomes Outcomes measured at 17 weeks from the beginning of the treatment. Retention time in treatment.
Opioids and cocaine use: measured by urine samples collected three times a week.
Drug abstinence measured by monday urine samples. Urine samples assayed in triplicate using radioim-




Methods RCT - Double blind, single-site, controlled study, with stratified randomization.
quality class: A
Participants 220 patients aged 21-55 years with a diagnosis of opioid dependence according to DSM IV, no serious
medical or psychiatric illnesses requiring long-term medication, recent opioid use on toxicologic screening,
negative serum pregnancy test.
55 patients in each treatment group. Enrollment period: January 1996 - November 1997.
Baltimore, USA.
Interventions Four treatment groups:
- levomethadyl acetate, 75-115 mg, 3 times a week (n=55)
- buprenorphine, 16-32 mg, 3 times a week (n=55)
- methadone, 60-100 mg daily (n=55)
- methadone 20 mg daily (n=55)
Induction phase: weeks 1 and 2. Maintenance phase: weeks 3 to 17. Patients assigned to high dose MM
started with 20 mg, with 10 mg increases administered daily until the dose reached 60 mg. Low dose MM
patients continued to receive 20 mg daily.
Outcomes Treatment retention at 17 weeks.
Opioid and cocaine use measured by urine specimens collected 3 times a week and analysed by enzyme
multiplied immunoassay technique (cut off: 300 ng/ml).
Degree of continuous abstinence from opioid or cocaine use, defined by at least 12 consecutive opioid or
cocaine-free urine specimens.
Side effects of treatment.
Self-reported opioid use.
Notes ITT analysis.
Missing samples were considered positive for purposes of analysis.
Allocation concealment B
Study Kosten-Oliveto 1993
Methods RCT - 24 weeks, double blind, double dummy, randomized clinical trial.
quality class: B
Participants 140 patients meeting DSM-III-R criteria for opioid dependence, with at least a 1-year history of opioid abuse,
prior treatment, positive urine screen for opioids and naloxone-precipitated opioid withdrawal symptoms.
New Haven - Cunnecticut, USA. Study period not specified.
Interventions Patients were randomly assigned to one of four treatment groups:
- buprenorphine 2 mg/day (n=28)
- buprenorphine 6 mg/day (n=28)
- methadone 35 mg/day (n=34)
- methadone 65 mg/day (n=35)
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Patients received both an oral and sublingual vehicle, one of which contained the active compound. All medi-
cations were given under nursing supervision once daily, and the dosage was started at 2 mg of buprenorphine
or 35 mg of methadone daily, and gradually increased to 6 mg of buprenorphine or 65 mg of methadone
during the first 2 weeks. Doses were maintained stable for a period of 17 weeks. subsequently, patients
underwent a gradual reduction in dose over 4-5 weeks.
Over the study period, patients were treated with relapse-prevention group therapy.
Outcomes Treatment retention.
Self reported drug use.
Opioid withdrawal symptoms.
Drug use, measured by urine samples collected weekly, randomly on Monday or Tuesday, and tested using
the Abbott Diagnostic radioimmunoassay drug detection system (cut off: 200 ng/ml). Opioid withdrawal
symptoms were self-reported on a weekly basis, evaluated by a 25-items opioid withdrawal rating form and
rated on a 75-point scale.
Cocaine withdrawal symptoms were self-reported on a weekly basis and rated on a 24-point scale.
Notes No ITT analysis.
15 patients of the original sample were excluded because they completed less than 3 weeks in the study.




Methods RCT - 40 weeks (280 days) double blind, randomized clinical trial.
quality class: B
Participants 430 subjects, meeting Food and Drug Administration criteria for admission to methadone maintenance,
aged 18-60 years, no major psychiatric or medical illnesses, no current alcoholism, no pending criminal
charges. Veteran Administration Hospitals, USA, April 1973 - March 1975.
Interventions Patients were randomly assigned to one of three groups:
- methadone 50 mg/day (n=146)
- methadone 100 mg/day (n=142)
- levomethadyl acetate 80 mg/day (n=142)
Methadyl acetate group received active medication on Monday, Wednesday, Friday, with placebo on all other
days. The first dose was 30 mg in all three groups, incremented by 10 mg on each succeeding Monday until
the patient achieved his target dose. All doses were dispensed double-blind.
Outcomes Treatment retention.
Drug use, measured by urine samples collected weekly using a random testing sequence supplied centrally.
Safety (side effects).
Notes All patients were male (veterans).
High attrition rate (58%).
Allocation concealment B
Study Ling 1996
Methods RCT - Double blind, randomized, controlled trial.
quality class: A
Participants 225 patients, aged 18-65 years, in good general health, meeting DSM-III-R criteria for opiod dependence and
the FDA criteria for methadone maintenance treatment, not currently enrolled in a methadone maintenance
program. Exclusion criteria: acute medical conditions, dependence to other drugs, pregnancy. October 1990
- September 1992.
Los Angeles, California, USA.
18Methadone maintenance at different dosages for opiod dependence (Review)
Copyright ©2005 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
Characteristics of included studies (Continued )
Interventions Patients were randomly assigned to one of three groups:
- buprenorphine 8 mg/day (n=75)
- methadone 30 mg/day (n=75)
- methadone 80 mg/day (n=75)
Each patient received both an oral and sublingual form of medication, only one of which was active. For
patients assigned to 80 mg methadone/day, the dose was increased by 5 mg daily until the 80 mg dose was
reached.
Outcomes Treatment retention at 26 and 52 weeks.
Use of drugs, measured by urine samples collected three times a week on Monday, Wednesday and Friday
and analyzed for opioids in the form of morphine by fluorescence polarization immunoassay (FPI) using the







Participants 610 chronic opioid users admitted to methadone maintenance program located in San Antonio - Texas,
USA, during the years 1989-1991.
Interventions Methadone maintenance at different dosages. The physician tended to regulate the dose according to needs
expressed by patients. The starting dose was 30 mg, increased by 10 mg daily until the stabilization dose. Till
the 3rd month continued heroin use led to dose increase, after the 3rd month it led to program probation
with the requirement of negative urine test for 3 months. A positive test then led to involuntary withdrawal
and discharge.
Outcomes Treatment retention at 1 year follow-up.
Data were collected by interview with subjects at the time of the admission, by review of clinical record 1
year after admission, and by follow-up interviews as soon as possible after the first anniversary of admission.
Urine specimens were collected once per month on randomly selected days and screened by enzyme im-
munoassay; positive tests were confirmed by thin-layer chromatography.
Notes No data suitable for inclusion in the tables.
OR of increase in retention per 10 mg increase in methadone dose.
Allocation concealment D
Study Preston 2000
Methods RCT - Double blind, randomized controlled trial.
quality class: A
Participants 285 patients admitted to methadone maintenance program at the Archway Clinic - Baltimore, USA.
Inclusion criteria: age 18-65 years, history of drug use by injection, qualified for methadone maintenance ac-
cording to Food and Drug Administration guidelines, no current dependence on alcohol or benzodiazepines,
at least 3 of 15 urine specimens collected during a 5 week baseline positive for heroin, no major medical or
psychiatric illnesses. Study period not specified.
Interventions Throughout the study (5 weeks baseline + 8 weeks intervention) all patients received daily methadone
maintenance and weekly counseling. Patients were randomly assigned to one of four groups:
- methadone 50 mg/day and contingent voucher for opiate-negative urine specimens (n=29)
- methadone 70 mg/day (n=31)
- methadone 70 mg/day and contingent voucher (n=32)
- methadone 50 mg/day (n=28)
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Dose was stabilized at 50 mg within the first week of treatment and held constant through the 5 weeks
baseline. Dose increases were given as 60 mg on days 1 through 3 and 70 mg on day 4 of the intervention.
Dose assignment was blinded to patients, treatment and research staff.
Outcomes Treatment retention at 13 weeks.
Opiate and cocaine use, measured by urine specimens collected three times a week and analysed using enzyme
multiplied immunoassay technique (cut off: 300 ng/ml).
A self reported drug use questionnaire was administered immediately after urine specimens collection.
Lifestyle changes (criminal activity and drug use during previous week) and craving questionnaire were
administered once a week (Wednesday).
Notes Only comparison standard and dose increase groups (non contingent) were taken into account in the review.
Allocation concealment B
Study Rhoades 1998
Methods RCT - Single blind randomised trial. quality class: C
Participants 142 patients aged 18-50 years, meeting DSM-III-R criteria for opioid dependence, in good physical and
psychiatric health.
Houston-Texas, USA. Study period not specified.
Interventions Subjects were randomly assigned to 50 or 80 mg of methadone per day and to 2 or 5 visits per week. Study
phases were: intake, stabilization, 24 weeks treatment. Subjects received about $14.00 per week for research
elements as well as bus or parking tokens. Before and after the HIV testing, proper counseling was provided.
Outcomes Treatment retention at 24 weeks, drug use, craving. Administered questionnaires:
- structured clinical interview for DSM-III-R
- Addiction Severity Index
- Hamilton Depression/Anxiety
- Beck Depression Inventory
- Profile of Mood States
- Medication Side Effects Questionnaire
- Drug History
- Desire to Use Drugs Inventory
Urine samples were split with half retained for retesting in a certified on-site laboratory. Qualitative testing
was by Syva EMIT System and the toxi-lab thin layer chromatographic system.
Notes Single blind.
Attrition bias.
123 subjects out of 142 began the stabilization period, but 16 did not complete it.




Methods RCT - Double blind randomized clinical trial.
quality class: A
Participants 116 subjects meeting FDA criteria for methadone maintenance treatment, fulfilling DSM-III R criteria for
both opioids and cocaine dependence, and having an opiate positive urine toxicology test at baseline. A
naloxone challenge test was used to verify current physiologic opioid dependence in subjects with no history
of methadone maintenance. New Haven, Connecticut.
January 1991 - July 1993.
Interventions Subjects were randomly assigned to one of four treatment groups:
- 65 mg methadone/day (n=28)
- 20 mg methadone/day (n=30)
- 12 mg buprenorphine/day (n=29)
- 4 mg buprenorphine/day (n=29)
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After 2 weeks of induction, subjects were maintained at their full maintenance dose for 22 weeks. Subjects
participated in a 1-hour weekly group counseling session.
Outcomes Retention in treatment at 24 weeks.
Opiod use and cocaine use, assessed by urine samples obtained twice a week during the first 9 months of the
study and thrice weekly between September 1991 and July 1993.
Samples were tested with Abbott Tdx system (cut off: 200 ng/ml for opioids, 300 ng/ml for cocaine). Weekly
self-report ratings of drug use were collected by the Weekly Drug Use Inventory.
Notes At the conclusion of the study, 16 of initial 132 subjects randomly assigned to the treatments were deemed
ineligible because they did not satisfy the eligibility criteria regarding cocaine dependence or abuse (4 subjects
from each of the 4 maintenance treatments).
At the end of the study, differences in retention among the 4 maintenance groups were not statistically




Methods RCT - Randomized, double blind, placebo-controlled study. quality class: B
Participants 247 patients aged 18-50 years, with a history of intravenous opiod dependence, no chronic medical or
psychiatric illnesses, a negative pregnancy test for women, and at least 3 months since the last treatment.
September 1988 - July 1990. Baltimore, USA.
Interventions 6 months short-term methadone treatment program (182 days). All participants received a minimum of 35
days of active methadone (stable or decreasing) during the first 5 weeks of treatment and then 15 weeks of
stable doses at:
- 50 mg (n=84)
- 20 mg (n=82)
- detoxification group: 0 mg/day (n=81).
During weeks 21 through 26, the methadone dose was gradually tapered. Individual counseling and group
therapy were offered. Treatment group assignment, stabilization doses and dosing schedules were double-
blind for all patients and the clinic staff who had patient contact.
Outcomes Treatment retention at 20 weeks.
Opioid and cocaine use through week 20, measured by urine samples collected 3 times a week. Samples were
tested on site using EMIT (cut off: 300 microg/ml); one sample each week was randomly selected to be sent




Methods RCT - 40-weeks randomized, double blind clinical trial.
quality class: A
Participants 192 patients aged >18 years, with at least 2 previous detoxication attempts or a single MMT, current
intravenous opioid dependence, no chronic medical or psychiatric illnesses, negative pregnancy test, at least
1 month since the patient’s last treatment at the clinic. June 1992 - October 1995. Baltimore, USA.
Interventions Patients were admitted to one of two methadone dose schedules:
- 40 to 50 mg/day (n=97)
- 80 to 100 mg/day (n=95), with concurrent couselling. Group assignment and methadone dosing were
double-blind for patients and staff. During the first week all participants received 30 mg of methadone daily.
Over the subsequent 5 weeks, patients in the high dose condition had dose increases of 10 mg per week, and
patients in the moderate dose condition had dose increases of 2 mg per week. Beginning in week 6 patients
achieved the stabilization dosages (80 mg and 40 mg). Through week 8 to 30 patients were eligible to receive
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double-blind dose increases (based on opioid use) and decreases (request of the patient or consecutive opioid
negative samples). through week 31 to 40, dose was tapered at a rate of 10% per week.
Outcomes Treatment retention.
Self-reported illicit opioid use.
Use of drugs measured by urine samples collected twice weekly and tested using enzyme-multiplied im-






Participants 370 heroin addicts meeting DSM-III-R criteria for opioid dependence, admitted for the first time to a
methadone maintenance treatment program at the Centro de Atencion y Seguimento between March 1991
and December 1994.
Barcelona, Spain.
Interventions Methadone maintenance at different dosages:
- <=80 mg/day (n=244)
- > 80 mg/day (n=126) Low-threshold treatment not abstinence-oriented. Patients are not aware of the
methadone dose dispensed. High-dose policy (no upper limit) and no restriction on long-term treatment
(no time limit).
Outcomes Treatment retention at 2 years follow-up.
Medical rcords were used to obtain data regarding patients. Heroin and cocaine use was monitored by
urinalyses carried out weekly.
Notes Baseline group for RR: >80 mg/day.
Allocation concealment D
Study Van Ameijden 1999
Methods CPS
quality class: B
Participants 498 injecting drug users with a Dutch nationality, enrolled for the Amsterdam Cohort Study via methadone
maintenance programs and a sexually transmitted diseases clinic.
Enrollment started in 1985; follow-up: April 1989 - May 1995.




Outcomes All cause mortality, overdose mortality.
Vital status was determined using local and national population registries, and causes of death were verified
and completed using hospital records, data from the drug department and postmortem examinations.
Follow-up was undertaken every 4 months.
Notes
Allocation concealment D
Characteristics of excluded studies
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Blaney 1999 CPS. Naturalistic approach: patients were not randomly assigned to a given dose level. No confounding adjustment
at the analysis stage.
Borg 1999 CPS. No confounding adjustment.
Brown CPS. Random samples of subjects extracted from different treatment programs. No random allocation of treat-
ments, no confounding adjustment at the analysis stage.
Caplehorn 1993a CPS. Secondary analysis of the original study (Caplehorn 1991, included).
Caplehorn 1993b CPS. Secondary analysis of a subsample of the original study (Caplehorn 1991, included).
De Leon 1995 CPS. Inadequate control for confounding factors: only employment status is included in the multivariate regression
model.
Handal 1976 CPS. Selection bias; no confounding adjustment at the analysis stage.
Hartel 1998 Retrospective ascertainment of exposure.
Havassy 1984 RCT. Randomization failed. Inadequate control of confounding variables.
Joe 1991 CPS. The multivariate regression model containing methadone dosage has been performed without main con-
founders (included in others models without dosage).
Langendam 2000a CPS. The effect of methadone dosage on overdose mortality was not evaluated in multivariate analysis.
Maxwell 1999 CPS. No confounding adjustment at the analysis stage.
McGlothlin 1981 CPS. Selection bias; no confounding adjustment at the analysis stage.
Mino 1998 CPS. Inadequate control of confounding factors. The final multivariate model does not contain all the variables
related to the outcome in the univariate analysis.
Panell 1977 RCT. Analysis of a subsample of the national study (Ling 1976, included).
Saxon 1996 RCT. Comparison is made between different contingency counseling approaches and non-contingency ones.
Schut 1973 CPS. Selection bias; no control of confounding variables at the analysis stage.
Seow 1980 CPS. No measures adjusted for confounding variables are presented.
Siassi 1977a CPS. Selection bias; no confounding adjustment at the analysis stage.
Siassi 1977b CPS. Selection bias. No confounding adjustment. at the analysis stage.
Stine 1992 CPS. Evaluation of the effect of 2 contingency management programs on cocaine abuse. Methadone dose was low-
ered in response to cocaine-positive urines and raised in response to abstinence. Exposure variables are approaches,
not dosages.
Strain 1993b RCT. Secondary analysis of a subsample of the original study (Strain 1993a, included).
Williams 1970 CPS. No measurement of attrition. Separate evaluation of low and high dosage groups. No effect measures at the
analysis stage. No control of confounding variables.
A D D I T I O N A L T A B L E S
Table 01 CPS - RR of leaving methadone maintenance treatment
Study
RR - 30 mg/
day
RR - 60 mg/
day
RR - 90 mg/
day p
Caplehorn 1991 (1.2 years follow-up) 1 0.40 (0.21,0.61) 0.13 (0.05,0.34)
Caplehorn 1994 (3 years follow-up) 1 0.56 0.12 <0.05
Caplehorn 1996 (0.4-1.66 years follow-up) 1 (50 mg) 0.28 (0.17,0.47)
Gaughwin 1998 (0-10 years follow-up) 1 0.40 0.00 <0.01
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participants Statistical method Effect size
01 Retention rate Relative Risk (Fixed) 95% CI Subtotals only
02 Retention time (weeks) Weighted Mean Difference (Fixed) 95% CI Subtotals only
03 Opioid use (self-
reported - times/
week)
Weighted Mean Difference (Fixed) 95% CI Subtotals only
04 Opioid use (self-reported mg/
day)
1 59 Weighted Mean Difference (Fixed) 95% CI -0.31 [-0.70, 0.08]
05 Opiod abstinence score 1 150 Weighted Mean Difference (Fixed) 95% CI 24.80 [8.91, 40.69]
06 Opioid abstinence at >3-4
weeks (urine based)
Relative Risk (Fixed) 95% CI Subtotals only
07 Opioid withdrawal symptoms
scores
Weighted Mean Difference (Fixed) 95% CI Subtotals only
08 Cocaine use (self-
reported - times/
week )
1 59 Weighted Mean Difference (Fixed) 95% CI 0.80 [-0.88, 2.48]
09 Cocaine abstinence at >3-4
weeks (urine-based)
2 168 Relative Risk (Fixed) 95% CI 1.81 [1.15, 2.85]
10 Cocaine withdrawal symptoms
scores
1 59 Weighted Mean Difference (Fixed) 95% CI 0.00 [-2.12, 2.12]
11 Side effects (at least 1) 1 110 Relative Risk (Fixed) 95% CI 1.14 [0.74, 1.75]
12 Criminal activity (mean
nb./week)
1 59 Weighted Mean Difference (Fixed) 95% CI 0.05 [-0.03, 0.13]
13 Money spent/
day






participants Statistical method Effect size
01 Overdose mortality (6 years
follow-up)
Relative Risk (Fixed) 95% CI Subtotals only
02 Leaving treatment (12-24
months follow-up, all studies)
Relative Risk (Fixed) 95% CI Subtotals only
C O V E R S H E E T
Title Methadone maintenance at different dosages for opiod dependence
Authors Faggiano F, Vigna-Taglianti F, Versino E, Lemma P
Contribution of author(s) FF, PL and EV conceptualised the review; FV-T and EV performed the literature searches
and organised papers collection. FF, FV-T and EV reviewed the papers and coded data
from the papers for meta-analysis. FF wrote results, discussion and conclusions sections.
FV-T wrote methods, description of studies and methodological quality of included studies
sections. EV provided comments and participated to the completion of the report.
Issue protocol first published 2000/3
24Methadone maintenance at different dosages for opiod dependence (Review)
Copyright ©2005 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
Review first published 2003/3
Date of most recent amendment 03 February 2005
Date of most recent
SUBSTANTIVE amendment
02 May 2003
What’s New Information not supplied by author
Date new studies sought but
none found
Information not supplied by author
Date new studies found but not
yet included/excluded
Information not supplied by author
Date new studies found and
included/excluded
Information not supplied by author
Date authors’ conclusions
section amended
Information not supplied by author
Contact address Prof Fabrizio Faggiano MD
Associate Professor
Department of Medical Sciences





Telephone: +39 0321 660661
E-mail: fabrizio.faggiano@med.unipmn.it
Facsimile: +39 011 480633
Cochrane Library number CD002208
Editorial group Cochrane Drugs and Alcohol Group
Editorial group code HM-ADDICTN
G R A P H S A N D O T H E R T A B L E S
25Methadone maintenance at different dosages for opiod dependence (Review)
Copyright ©2005 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
Fig. 1. Comparison 01 RCT
01.01 Retention rate
Review: Methadone maintenance at different dosages for opiod dependence
Comparison: 01 RCT
Outcome: 01 Retention rate
Study Treatment Control Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
01 60-109 mg/day vs 1-39 mg/day (at 17-26 weeks)
Johnson 1992 17/54 11/55 10.7 1.57 [ 0.81, 3.04 ]
Johnson 2000 39/55 11/55 10.8 3.55 [ 2.04, 6.18 ]
Kosten-Oliveto 1993 21/35 23/34 22.9 0.89 [ 0.62, 1.27 ]
Ling 1996 43/75 43/75 42.3 1.00 [ 0.76, 1.32 ]
Schottenfeld 1997 18/28 14/30 13.3 1.38 [ 0.86, 2.21 ]
Subtotal (95% CI) 247 249 100.0 1.36 [ 1.13, 1.63 ]
Total events: 138 (Treatment), 102 (Control)
Test for heterogeneity chi-square=21.94 df=4 p=0.0002 I? =81.8%
Test for overall effect z=3.30 p=0.001
02 60-109 mg/day vs 1-39 mg/day (at 52 weeks)
Ling 1996 26/75 16/75 100.0 1.63 [ 0.95, 2.77 ]
Subtotal (95% CI) 75 75 100.0 1.63 [ 0.95, 2.77 ]
Total events: 26 (Treatment), 16 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=1.78 p=0.07
03 60-109 mg/day vs 40-59 mg/day (at 7-13 weeks)
Ling 1976 111/142 110/146 79.3 1.04 [ 0.91, 1.18 ]
Preston 2000 27/31 27/28 20.7 0.90 [ 0.78, 1.05 ]
Subtotal (95% CI) 173 174 100.0 1.01 [ 0.91, 1.12 ]
Total events: 138 (Treatment), 137 (Control)
Test for heterogeneity chi-square=2.21 df=1 p=0.14 I? =54.8%
Test for overall effect z=0.18 p=0.9
04 60-109 mg/day vs 40-59 mg/day (at 27-40 weeks)
Goldstein 1973 26/40 15/40 11.7 1.73 [ 1.09, 2.75 ]
Ling 1976 74/142 61/146 46.8 1.25 [ 0.97, 1.60 ]
Strain 1999 57/95 54/97 41.6 1.08 [ 0.85, 1.37 ]
Subtotal (95% CI) 277 283 100.0 1.23 [ 1.05, 1.45 ]
Total events: 157 (Treatment), 130 (Control)
Test for heterogeneity chi-square=3.30 df=2 p=0.19 I? =39.5%
Test for overall effect z=2.53 p=0.01
0.2 0.5 1 2 5
Favours control Favours treatment (Continued . . . )
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(. . . Continued)
Study Treatment Control Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
05 40-59 mg/day vs 1-39 mg/day (at 20 weeks)
Strain 1993a 44/84 34/82 100.0 1.26 [ 0.91, 1.75 ]
Subtotal (95% CI) 84 82 100.0 1.26 [ 0.91, 1.75 ]
Total events: 44 (Treatment), 34 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=1.40 p=0.2
06 >110 mg/day vs 40-59 mg/day (at 27 weeks)
Goldstein 1973 25/40 15/40 100.0 1.67 [ 1.05, 2.66 ]
Subtotal (95% CI) 40 40 100.0 1.67 [ 1.05, 2.66 ]
Total events: 25 (Treatment), 15 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=2.15 p=0.03
07 >110 mg/day vs 60-109 mg/day (at 27 weeks)
Goldstein 1973 25/40 26/40 100.0 0.96 [ 0.69, 1.34 ]
Subtotal (95% CI) 40 40 100.0 0.96 [ 0.69, 1.34 ]
Total events: 25 (Treatment), 26 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=0.23 p=0.8
0.2 0.5 1 2 5
Favours control Favours treatment
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Fig. 2. Comparison 01 RCT
01.02 Retention time (weeks)
Review: Methadone maintenance at different dosages for opiod dependence
Comparison: 01 RCT
Outcome: 02 Retention time (weeks)
Study Treatment Control Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 60-109 mg/day vs 1-39 mg/day
Johnson 2000 55 15.00 (4.24) 55 10.00 (4.24) 72.5 5.00 [ 3.42, 6.58 ]
Kosten-Oliveto 1993 35 19.00 (8.00) 34 21.00 (5.00) 18.5 -2.00 [ -5.14, 1.14 ]
Schottenfeld 1997 28 19.60 (8.10) 30 16.40 (9.30) 9.1 3.20 [ -1.28, 7.68 ]
Subtotal (95% CI) 118 119 100.0 3.54 [ 2.19, 4.89 ]
Test for heterogeneity chi-square=15.25 df=2 p=0.0005 I? =86.9%
Test for overall effect z=5.15 p<0.00001
03 60-109 mg/day vs 40-59 mg/day
Preston 2000 31 12.60 (1.30) 28 12.90 (0.30) 100.0 -0.30 [ -0.77, 0.17 ]
Subtotal (95% CI) 31 28 100.0 -0.30 [ -0.77, 0.17 ]
Test for heterogeneity: not applicable
Test for overall effect z=1.25 p=0.2
-10.0 -5.0 0 5.0 10.0
Favours control Favours treatment
Fig. 3. Comparison 01 RCT
01.03 Opioid use (self-reported - times/
week)
Review: Methadone maintenance at different dosages for opiod dependence
Comparison: 01 RCT
Outcome: 03 Opioid use (self-reported - times/week)
Study Treatment Control Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 60-109 mg/day vs 1-39 mg/day
Johnson 2000 55 4.00 (7.40) 55 6.00 (7.40) 100.0 -2.00 [ -4.77, 0.77 ]
Subtotal (95% CI) 55 55 100.0 -2.00 [ -4.77, 0.77 ]
Test for heterogeneity: not applicable
Test for overall effect z=1.42 p=0.2
03 60-109 mg/day vs 40-59 mg/day
Preston 2000 31 2.17 (3.08) 28 4.06 (2.94) 100.0 -1.89 [ -3.43, -0.35 ]
Subtotal (95% CI) 31 28 100.0 -1.89 [ -3.43, -0.35 ]
Test for heterogeneity: not applicable
Test for overall effect z=2.41 p=0.02
-10.0 -5.0 0 5.0 10.0
Favours treatment Favours control
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Fig. 4. Comparison 01 RCT
01.04 Opioid use (self-reported mg/
day)
Review: Methadone maintenance at different dosages for opiod dependence
Comparison: 01 RCT
Outcome: 04 Opioid use (self-reported mg/day)
Study Treatment Control Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
03 60-109mg/day vs 40-59 mg/day
Preston 2000 31 0.58 (0.78) 28 0.89 (0.74) 100.0 -0.31 [ -0.70, 0.08 ]
Total (95% CI) 31 28 100.0 -0.31 [ -0.70, 0.08 ]
Test for heterogeneity: not applicable
Test for overall effect z=1.57 p=0.1
-1.0 -0.5 0 0.5 1.0
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Fig. 5. Comparison 01 RCT
01.05 Opiod abstinence score
Review: Methadone maintenance at different dosages for opiod dependence
Comparison: 01 RCT
Outcome: 05 Opiod abstinence score
Study Treatment Control Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 60-109 mg/day vs 1-39 mg/day
Ling 1996 75 64.90 (52.50) 75 40.10 (46.60) 100.0 24.80 [ 8.91, 40.69 ]
Total (95% CI) 75 75 100.0 24.80 [ 8.91, 40.69 ]
Test for heterogeneity: not applicable
Test for overall effect z=3.06 p=0.002
-100.0 -50.0 0 50.0 100.0
Favours control Favours treatment
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Fig. 6. Comparison 01 RCT
01.06 Opioid abstinence at >3-4 weeks (urine based)
Review: Methadone maintenance at different dosages for opiod dependence
Comparison: 01 RCT
Outcome: 06 Opioid abstinence at >3-4 weeks (urine based)
Study Treatment Control Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
01 60-109 mg/day vs 1-39 mg/day
Johnson 2000 15/55 4/55 11.7 3.75 [ 1.33, 10.58 ]
Kosten-Oliveto 1993 22/35 23/34 68.4 0.93 [ 0.66, 1.31 ]
Schottenfeld 1997 17/28 7/30 19.8 2.60 [ 1.27, 5.31 ]
Subtotal (95% CI) 118 119 100.0 1.59 [ 1.16, 2.18 ]
Total events: 54 (Treatment), 34 (Control)
Test for heterogeneity chi-square=13.80 df=2 p=0.001 I? =85.5%
Test for overall effect z=2.88 p=0.004
03 60-109 mg/day vs 40-59 mg/day
Preston 2000 10/31 6/28 100.0 1.51 [ 0.63, 3.61 ]
Subtotal (95% CI) 31 28 100.0 1.51 [ 0.63, 3.61 ]
Total events: 10 (Treatment), 6 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=0.92 p=0.4
0.1 0.2 0.5 1 2 5 10
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Fig. 7. Comparison 01 RCT
01.07 Opioid withdrawal symptoms scores
Review: Methadone maintenance at different dosages for opiod dependence
Comparison: 01 RCT
Outcome: 07 Opioid withdrawal symptoms scores
Study Treatment Control Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 60-109 mg/day vs 1-39 mg/day
Kosten-Oliveto 1993 35 11.00 (10.00) 34 14.00 (13.00) 100.0 -3.00 [ -8.48, 2.48 ]
Subtotal (95% CI) 35 34 100.0 -3.00 [ -8.48, 2.48 ]
Test for heterogeneity: not applicable
Test for overall effect z=1.07 p=0.3
03 60-109 mg/day vs 40-59 mg/day
Preston 2000 31 24.37 (18.75) 28 30.19 (18.75) 100.0 -5.82 [ -15.40, 3.76 ]
Subtotal (95% CI) 31 28 100.0 -5.82 [ -15.40, 3.76 ]
Test for heterogeneity: not applicable
Test for overall effect z=1.19 p=0.2
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Fig. 8. Comparison 01 RCT
01.08 Cocaine use (self-reported - times/
week )
Review: Methadone maintenance at different dosages for opiod dependence
Comparison: 01 RCT
Outcome: 08 Cocaine use (self-reported - times/week )
Study Treatment Control Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 60-109 mg/day vs 1-39 mg/day
Kosten-Oliveto 1993 29 1.90 (4.30) 30 1.10 (1.70) 100.0 0.80 [ -0.88, 2.48 ]
Total (95% CI) 29 30 100.0 0.80 [ -0.88, 2.48 ]
Test for heterogeneity: not applicable
Test for overall effect z=0.93 p=0.4
-4.0 -2.0 0 2.0 4.0
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Fig. 9. Comparison 01 RCT
01.09 Cocaine abstinence at >3-4 weeks (urine-based)
Review: Methadone maintenance at different dosages for opiod dependence
Comparison: 01 RCT
Outcome: 09 Cocaine abstinence at >3-4 weeks (urine-based)
Study Treatment Control Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
01 60-109 mg/day vs 1-39 mg/day
Johnson 2000 21/55 8/55 40.8 2.63 [ 1.27, 5.41 ]
Schottenfeld 1997 14/28 12/30 59.2 1.25 [ 0.70, 2.22 ]
Total (95% CI) 83 85 100.0 1.81 [ 1.15, 2.85 ]
Total events: 35 (Treatment), 20 (Control)
Test for heterogeneity chi-square=2.62 df=1 p=0.11 I? =61.8%
Test for overall effect z=2.57 p=0.01
0.1 0.2 0.5 1 2 5 10
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Fig. 10. Comparison 01 RCT
01.10 Cocaine withdrawal symptoms scores
Review: Methadone maintenance at different dosages for opiod dependence
Comparison: 01 RCT
Outcome: 10 Cocaine withdrawal symptoms scores
Study Treatment Control Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 60-109 mg/day vs 1-39 mg/day
Kosten-Oliveto 1993 29 3.00 (4.20) 30 3.00 (4.10) 100.0 0.00 [ -2.12, 2.12 ]
Total (95% CI) 29 30 100.0 0.00 [ -2.12, 2.12 ]
Test for heterogeneity: not applicable
Test for overall effect z=0.00 p=1
-10.0 -5.0 0 5.0 10.0
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Fig. 11. Comparison 01 RCT
01.11 Side effects (at least 1)
Review: Methadone maintenance at different dosages for opiod dependence
Comparison: 01 RCT
Outcome: 11 Side effects (at least 1)
Study Treatment Control Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
01 60-109 mg/day vs 1-39 mg/day
Johnson 2000 25/55 22/55 100.0 1.14 [ 0.74, 1.75 ]
Total (95% CI) 55 55 100.0 1.14 [ 0.74, 1.75 ]
Total events: 25 (Treatment), 22 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=0.58 p=0.6
0.1 0.2 0.5 1 2 5 10
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Fig. 12. Comparison 01 RCT
01.12 Criminal activity (mean nb./week)
Review: Methadone maintenance at different dosages for opiod dependence
Comparison: 01 RCT
Outcome: 12 Criminal activity (mean nb./week)
Study Treatment Control Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
03 60-109 mg/day vs 40-59 mg/day
Preston 2000 31 0.08 (0.17) 28 0.03 (0.16) 100.0 0.05 [ -0.03, 0.13 ]
Total (95% CI) 31 28 100.0 0.05 [ -0.03, 0.13 ]
Test for heterogeneity: not applicable
Test for overall effect z=1.16 p=0.2
-0.5 -0.25 0 0.25 0.5
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Fig. 13. Comparison 01 RCT
01.13 Money spent/
day
Review: Methadone maintenance at different dosages for opiod dependence
Comparison: 01 RCT
Outcome: 13 Money spent/day
Study Treatment Control Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
03 60-109 mg/day vs 40-59 mg/day
Preston 2000 31 2.98 (5.40) 28 4.98 (5.34) 100.0 -2.00 [ -4.74, 0.74 ]
Total (95% CI) 31 28 100.0 -2.00 [ -4.74, 0.74 ]
Test for heterogeneity: not applicable
Test for overall effect z=1.43 p=0.2
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Fig. 14. Comparison 02 CPS
02.01 Overdose mortality (6 years follow-up)
Review: Methadone maintenance at different dosages for opiod dependence
Comparison: 02 CPS
Outcome: 01 Overdose mortality (6 years follow-up)
Study Treatment Control Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
01 >75 mg/day vs 5-55 mg/day
Van Ameijden 1999 0/316 4/822 100.0 0.29 [ 0.02, 5.34 ]
Subtotal (95% CI) 316 822 100.0 0.29 [ 0.02, 5.34 ]
Total events: 0 (Treatment), 4 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=0.83 p=0.4
02 >75 mg/day vs 55-70 mg/day
Van Ameijden 1999 0/316 1/362 100.0 0.38 [ 0.02, 9.34 ]
Subtotal (95% CI) 316 362 100.0 0.38 [ 0.02, 9.34 ]
Total events: 0 (Treatment), 1 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=0.59 p=0.6
03 55-70 mg/day vs 5-55 mg/day
Van Ameijden 1999 1/362 4/822 100.0 0.57 [ 0.06, 5.06 ]
Subtotal (95% CI) 362 822 100.0 0.57 [ 0.06, 5.06 ]
0.1 0.2 0.5 1 2 5 10
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(. . . Continued)
Study Treatment Control Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
Total events: 1 (Treatment), 4 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=0.51 p=0.6
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Fig. 15. Comparison 02 CPS
02.02 Leaving treatment (12-24 months follow-up, all studies)
Review: Methadone maintenance at different dosages for opiod dependence
Comparison: 02 CPS
Outcome: 02 Leaving treatment (12-24 months follow-up, all studies)
Study Treatment Control Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
04 high dose vs middle dose
D’Ippoliti 1998 41/158 142/384 86.6 0.70 [ 0.52, 0.94 ]
Del Rio 1997 6/33 14/39 13.4 0.51 [ 0.22, 1.17 ]
Subtotal (95% CI) 191 423 100.0 0.68 [ 0.51, 0.89 ]
Total events: 47 (Treatment), 156 (Control)
Test for heterogeneity chi-square=0.52 df=1 p=0.47 I? =0.0%
Test for overall effect z=2.78 p=0.006
05 middle dose vs low dose
D’Ippoliti 1998 142/384 87/113 97.8 0.48 [ 0.41, 0.57 ]
Del Rio 1997 14/39 3/39 2.2 4.67 [ 1.46, 14.97 ]
Subtotal (95% CI) 423 152 100.0 0.57 [ 0.48, 0.67 ]
Total events: 156 (Treatment), 90 (Control)
Test for heterogeneity chi-square=16.75 df=1 p=<0.0001 I? =94.0%
Test for overall effect z=6.65 p<0.00001
06 high dose vs low dose
D’Ippoliti 1998 41/158 87/113 61.3 0.34 [ 0.25, 0.45 ]
Del Rio 1997 6/33 3/39 1.7 2.36 [ 0.64, 8.73 ]
Torrens 1996 13/126 90/244 37.0 0.28 [ 0.16, 0.48 ]
Subtotal (95% CI) 317 396 100.0 0.35 [ 0.27, 0.45 ]
Total events: 60 (Treatment), 180 (Control)
Test for heterogeneity chi-square=8.94 df=2 p=0.01 I? =77.6%
Test for overall effect z=8.14 p<0.00001
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